{"id":58002,"date":"2026-02-26T14:21:50","date_gmt":"2026-02-26T06:21:50","guid":{"rendered":"https:\/\/flcube.com\/?p=58002"},"modified":"2026-02-26T14:21:51","modified_gmt":"2026-02-26T06:21:51","slug":"novartis-to-build-23b-rlt-manufacturing-site-in-texas-expands-radioligand-therapy-production-capacity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58002","title":{"rendered":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity"},"content":{"rendered":"\n<p><strong>Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a>)<\/strong> announced plans to establish a new <strong>46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site<\/strong> in <strong>Denton, Texas<\/strong>. The facility represents continued execution of the company&#8217;s <strong>USD\u202f23\u202fbillion investment commitment<\/strong> in the United States and will expand domestic production capacity for its growing <strong>radioligand therapy portfolio<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-overview\">Investment Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novartis (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Facility Type<\/strong><\/td><td>Radioligand therapy (RLT) manufacturing site<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>Denton, Texas<\/td><\/tr><tr><td><strong>Facility Size<\/strong><\/td><td>46,000 square feet<\/td><\/tr><tr><td><strong>Strategic Context<\/strong><\/td><td>Part of USD\u202f23\u202fbillion US investment commitment<\/td><\/tr><tr><td><strong>Construction Start<\/strong><\/td><td>2026<\/td><\/tr><tr><td><strong>Operational Target<\/strong><\/td><td>2028<\/td><\/tr><tr><td><strong>Job Creation<\/strong><\/td><td>New positions in bioengineering, advanced manufacturing, quality, operations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-radioligand-therapy-context\">Radioligand Therapy Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Technology<\/strong><\/td><td>Targeted radiopharmaceuticals delivering therapeutic radiation to cancer cells<\/td><\/tr><tr><td><strong>Novartis Portfolio<\/strong><\/td><td>Pluvicto (PSMA\u2011targeted for prostate cancer), Lutathera (SSTR\u2011targeted for neuroendocrine tumors)<\/td><\/tr><tr><td><strong>Manufacturing Complexity<\/strong><\/td><td>Short half\u2011life isotopes require proximity to patients; decentralized production network critical<\/td><\/tr><tr><td><strong>Market Growth<\/strong><\/td><td>RLT market projected to exceed $10\u202fbillion by 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Manufacturing Expansion:<\/strong> The Denton site addresses <strong>supply constraints<\/strong> for Pluvicto and Lutathera, which face high demand and manufacturing bottlenecks limiting patient access.<\/li>\n\n\n\n<li><strong>Geographic Diversification:<\/strong> Texas location complements existing Novartis RLT facilities (e.g., New Jersey, Illinois), creating <strong>redundant production capacity<\/strong> and reducing logistics risks for time\u2011sensitive radiopharmaceuticals.<\/li>\n\n\n\n<li><strong>Workforce Development:<\/strong> Job creation in <strong>bioengineering and advanced manufacturing<\/strong> supports local economic growth while addressing talent needs for specialized radiopharmaceutical production.<\/li>\n\n\n\n<li><strong>Investment Commitment Execution:<\/strong> The facility demonstrates progress against Novartis&#8217;s <strong>USD\u202f23\u202fbillion US pledge<\/strong>, balancing manufacturing expansion with R&amp;D and commercial infrastructure investments.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Pluvicto Demand<\/strong><\/td><td>Prostate cancer RLT faces supply shortages; additional capacity enables market expansion and reduced wait times<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Manufacturing scale reinforces Novartis leadership in RLT vs. emerging competitors (Bayer, POINT Biopharma)<\/td><\/tr><tr><td><strong>Texas Life Sciences Ecosystem<\/strong><\/td><td>Denton facility joins growing biopharma manufacturing corridor in North Texas<\/td><\/tr><tr><td><strong>Patient Access<\/strong><\/td><td>Increased US production capacity supports broader reimbursement and clinical adoption<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding construction timelines, operational readiness, and production capacity expansion. Actual results may differ due to risks including regulatory approvals, construction delays, and isotope supply chain challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58004,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[140,865],"class_list":["post-58002","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company&#039;s USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58002\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company&#039;s USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58002\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-26T06:21:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-26T06:21:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity\",\"datePublished\":\"2026-02-26T06:21:50+00:00\",\"dateModified\":\"2026-02-26T06:21:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2603.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58002#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58002\",\"name\":\"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2603.webp\",\"datePublished\":\"2026-02-26T06:21:50+00:00\",\"dateModified\":\"2026-02-26T06:21:51+00:00\",\"description\":\"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company's USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58002\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58002#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company's USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58002","og_locale":"en_US","og_type":"article","og_title":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity","og_description":"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company's USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.","og_url":"https:\/\/flcube.com\/?p=58002","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-26T06:21:50+00:00","article_modified_time":"2026-02-26T06:21:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58002#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58002"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity","datePublished":"2026-02-26T06:21:50+00:00","dateModified":"2026-02-26T06:21:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58002"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58002#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","keywords":["Novartis","NYSE: NVS"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58002#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58002","url":"https:\/\/flcube.com\/?p=58002","name":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58002#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58002#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","datePublished":"2026-02-26T06:21:50+00:00","dateModified":"2026-02-26T06:21:51+00:00","description":"Novartis (NYSE:\u202fNVS) announced plans to establish a new 46,000\u2011square\u2011foot radioligand therapy (RLT) manufacturing site in Denton, Texas. The facility represents continued execution of the company's USD\u202f23\u202fbillion investment commitment in the United States and will expand domestic production capacity for its growing radioligand therapy portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58002#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58002"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58002#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","width":1080,"height":608,"caption":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58002#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis to Build $23B RLT Manufacturing Site in Texas \u2013 Expands Radioligand Therapy Production Capacity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58002"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58002\/revisions"}],"predecessor-version":[{"id":58005,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58002\/revisions\/58005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58004"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}